{"id":745221,"date":"2015-04-19T07:30:00","date_gmt":"2015-04-19T07:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/treatment-of-advanced-non-small-cell-lung-cancer-nsclc-with-keytruda-pembrolizumab-presented-at-aacr-annual-meeting-and-published-in-the-new-england-journal-of-medicine\/"},"modified":"2025-11-07T01:25:15","modified_gmt":"2025-11-07T06:25:15","slug":"treatment-of-advanced-non-small-cell-lung-cancer-nsclc-with-keytruda-pembrolizumab-presented-at-aacr-annual-meeting-and-published-in-the-new-england-journal-of-medicine","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/treatment-of-advanced-non-small-cell-lung-cancer-nsclc-with-keytruda-pembrolizumab-presented-at-aacr-annual-meeting-and-published-in-the-new-england-journal-of-medicine\/","title":{"rendered":"Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with KEYTRUDA\u00ae (pembrolizumab) Presented at AACR Annual Meeting and Published in the New England Journal of Medicine"},"content":{"rendered":"<p class=\"bwalignc\">       Data Formed the Basis for KEYTRUDA U.S. FDA Submission and        Breakthrough Therapy Designation in Advanced NSCLC     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced new data from KEYNOTE-001, a Phase 1b study evaluating<br \/>\n      KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab), the company\u2019s anti-PD-1 therapy,<br \/>\n      in na\u00efve and previously-treated patients with advanced non-small cell<br \/>\n      lung cancer (NSCLC). In an analysis of 313 patients from a validation<br \/>\n      data set for tumor PD-L1 expression, overall-response rate (ORR) was<br \/>\n      45.2 percent<sup>1<\/sup> (95% CI, 33.5-57.3) in patients with greater<br \/>\n      than or equal to (\u2265) 50 percent of tumor cells positive for PD-L1<br \/>\n      expression (n=73). In the other PD-L1 subgroups, ORR was 16.5 percent<br \/>\n      (95% CI, 9.9-25.1) in patients with 1-49 percent tumor cells positive<br \/>\n      (n=103) and 10.7 percent (95% CI, 2.3-28.2) in patients with less than 1<br \/>\n      percent tumor cells positive (n=28) for PD-L1 expression. In the total<br \/>\n      study population, ORR was 19.4 percent (95% CI, 16.0-23.2) (n=495),<br \/>\n      which was consistent with data previously presented from this study.<br \/>\n      These data from KEYNOTE-001 will be presented today by Dr. Edward Garon,<br \/>\n      Jonsson Comprehensive Cancer Center, University of California, Los<br \/>\n      Angeles at the American Association for Cancer Research (AACR) Annual<br \/>\n      Meeting (abstract #CT104), were part of the AACR press program, and were<br \/>\n      also published today in the <i>New England Journal of Medicine<\/i>.\n    <\/p>\n<p>\n      The efficacy findings demonstrated that tumor PD-L1 expression may be a<br \/>\n      relevant biomarker for the identification of NSCLC patients with an<br \/>\n      enhanced likelihood of experiencing improved efficacy with an anti-PD-1<br \/>\n      therapy. PD-L1 is a protein that may be overexpressed in the tumor and<br \/>\n      may contribute mechanistically to an inhibited immune response.\n    <\/p>\n<p>\n      \u201cIn this study, NSCLC patients whose tumors express PD-L1 in the<br \/>\n      majority of their cells experienced the highest response rates to<br \/>\n      KEYTRUDA treatment,\u201d said Dr. Roger Perlmutter, president, Merck<br \/>\n      Research Laboratories. \u201cThe results from this study formed the basis for<br \/>\n      our Breakthrough Therapy designation and our recent FDA submission for<br \/>\n      advanced NSCLC, and indicate that tumor PD-L1 expression may be a<br \/>\n      relevant biomarker to identify patients more likely to have higher rates<br \/>\n      of response to KEYTRUDA in this tumor type.\u201d\n    <\/p>\n<p>\n      Merck recently announced that the company submitted a supplemental<br \/>\n      Biologics License Application (sBLA) for KEYTRUDA in advanced NSCLC with<br \/>\n      the U.S. Food and Drug Administration (FDA). (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fmerck.newshq.businesswire.com%2Fnews-release%2Foncology-newsroom%2Fmerck-announces-submission-supplemental-biologics-license-application&amp;esheet=51082747&amp;newsitemid=20150419005030&amp;lan=en-US&amp;anchor=link&amp;index=1&amp;md5=1b0f845fffe6e3314f66e13f6f2db134\" rel=\"nofollow\">link<\/a>)<br \/>\n      Under PDUFA, the FDA has 60 days from submission of the sBLA to<br \/>\n      determine if the application will be accepted for review. KEYTRUDA was<br \/>\n      granted Breakthrough Therapy designation in advanced NSCLC by the U.S<br \/>\n      Food and Drug Administration (FDA) in October 2014.\n    <\/p>\n<p>\n      <b>Additional Findings from KEYNOTE-001 for the Total Evaluable<br \/>\n      Population<\/b>\n    <\/p>\n<p>\n      Data for progression-free survival (PFS) and overall survival (OS) based<br \/>\n      on tumor PD-L1 expression was also presented in 356 na\u00efve and<br \/>\n      previously-treated patients with advanced NSCLC (total evaluable for<br \/>\n      PD-L1 staining). In the \u226550 percent PD-L1 sub-group, median PFS (95% CI)<br \/>\n      was 6.3 months (2.9-12.5) (n=119); within this group, PFS was 6.1 months<br \/>\n      (2.1-12.5) for previously-treated patients (n=294) and 12.5 months<br \/>\n      (2.4-12.5) for naive patients (n=62). PFS was 3.3 months (95% CI,<br \/>\n      2.1-4.1) in the 1-49 percent PD-L1 sub-group (n=161), and 2.3 months<br \/>\n      (95% CI, 2.1-4.0) in less than 1 percent PD-L1 sub-group (n=76). Median<br \/>\n      OS had not yet been reached in the \u226550 percent PD-L1 sub-group,<br \/>\n      regardless of prior treatment. Median OS was 8.8 months for the other<br \/>\n      PD-L1 subgroups (95% CI, 6.8-12.4 for 1-49% sub-group and 5.5-12 for<br \/>\n      less than 1% sub-group, respectively), and was similar regardless of<br \/>\n      prior treatment.\n    <\/p>\n<p>\n      Median duration of response was similar across tumor PD-L1 expression<br \/>\n      subgroups; 12.5 months (2.1+ to 23.3)<sup>2<\/sup> for the \u226550 percent<br \/>\n      sub-group, 7.2 months (1.4+ to 8.3+)<sup>3<\/sup> for the 1-49 percent<br \/>\n      sub-group, and not reached (1.0+ to 10.8+)<sup>4<\/sup> in the less than<br \/>\n      1 percent sub-group. At the time of analysis, median follow-up duration<br \/>\n      was 10.9 months (range, 5.2\u201327.5).\n    <\/p>\n<p>\n      \u201cThese results represent the largest data set of an anti-PD-1 therapy in<br \/>\n      na\u00efve and previously-treated patients with advanced non-small cell lung<br \/>\n      cancer. We are advancing a broad Phase 3 program that will further<br \/>\n      characterize the potential benefit of KEYTRUDA compared to the standard<br \/>\n      of care in these patients,\u201d said Roger Dansey, therapeutic area head and<br \/>\n      senior vice president, oncology late-stage development, Merck Research<br \/>\n      Laboratories.\n    <\/p>\n<p>\n      Adverse events evaluated in the total study population were consistent<br \/>\n      with previously reported safety data for KEYTRUDA. The most common<br \/>\n      treatment-related adverse events were fatigue, pruritus, and decreased<br \/>\n      appetite. Grade 3-5 treatment-related adverse events occurred in 9.5<br \/>\n      percent of patients (n=47). Treatment-related adverse events of an<br \/>\n      inflammatory or immune-mediated nature that occurred in more than 2<br \/>\n      percent of patients were infusion-related reactions (n=15; 3.0%),<br \/>\n      hypothyroidism (n=34; 6.9%), and pneumonitis (n=18; 3.6%). One infusion<br \/>\n      reaction led to treatment discontinuation and all hypothyroidism cases<br \/>\n      were successfully managed with medical therapy. There was one<br \/>\n      treatment-related death (pneumonitis) and grade 3-5 pneumonitis was<br \/>\n      observed in 1.8 percent of patients (n=9). At the time of analysis, two<br \/>\n      pneumonitis cases were ongoing (both grade 1\u20132).\n    <\/p>\n<p>\n      <b>About the KEYNOTE-001 Study and Tumor PD-L1 Validation Data Set<\/b>\n    <\/p>\n<p>\n      KEYNOTE-001 is an ongoing multi-center, single-arm, open-label Phase 1b<br \/>\n      study evaluating KEYTRUDA in more than 1,000 patients with diverse<br \/>\n      late-stage cancers \u2013 predominantly lung and melanoma. Three dosing<br \/>\n      regimens were evaluated; 10mg\/kg every two weeks, 10mg\/kg every three<br \/>\n      weeks or 2mg\/kg every three weeks. The primary endpoints include ORR and<br \/>\n      safety; the secondary endpoints include PFS, OS and duration of<br \/>\n      response. Tumor response was assessed every 9 weeks per RECIST 1.1 by<br \/>\n      independent, central, blinded radiographic review. For the tumor PD-L1<br \/>\n      expression validation data set, tumor samples were contemporaneously<br \/>\n      collected within six months of staining and tumor PD-L1 expression was<br \/>\n      measured by Dako\u2019s immunohistochemistry companion diagnostic test PD-L1<br \/>\n      IHC 22C3 PharmDx. The training data set for tumor PD-L1 expression from<br \/>\n      KEYNOTE-001 was presented at the AACR Annual Meeting in April 2014.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><sup><b>\u00ae<\/b><\/sup><b> (pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) is a humanized monoclonal antibody that blocks<br \/>\n      the interaction between PD-1 and its ligands, PD-L1 and PD-L2. By<br \/>\n      binding to the PD-1 receptor and blocking the interaction with the<br \/>\n      receptor ligands, KEYTRUDA releases the PD-1 pathway-mediated inhibition<br \/>\n      of the immune response, including the anti-tumor immune response.\n    <\/p>\n<p>\n      KEYTRUDA is indicated in the United States at a dose of 2 mg\/kg<br \/>\n      administered as an intravenous infusion over 30 minutes every three<br \/>\n      weeks for the treatment of patients with unresectable or metastatic<br \/>\n      melanoma and disease progression following ipilimumab and, if BRAF V600<br \/>\n      mutation positive, a BRAF inhibitor. This indication is approved under<br \/>\n      accelerated approval based on tumor response rate and durability of<br \/>\n      response. An improvement in survival or disease-related symptoms has not<br \/>\n      yet been established. Continued approval for this indication may be<br \/>\n      contingent upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials.\n    <\/p>\n<p>\n      Merck is advancing a broad and fast-growing clinical development program<br \/>\n      for KEYTRUDA with more than 85 clinical trials \u2013 across more than 30<br \/>\n      tumor types and more than 14,000 patients \u2013 both as a monotherapy and in<br \/>\n      combination with other therapies.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><sup><b>\u00ae<\/b><\/sup>\n    <\/p>\n<p>\n      Pneumonitis occurred in 12 (2.9%) of 411 patients with advanced melanoma<br \/>\n      receiving KEYTRUDA (the approved indication in the United States),<br \/>\n      including Grade 2 or 3 cases in 8 (1.9%) and 1 (0.2%) patients,<br \/>\n      respectively. Monitor patients for signs and symptoms of pneumonitis.<br \/>\n      Evaluate suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4<br \/>\n      pneumonitis.\n    <\/p>\n<p>\n      Colitis (including microscopic colitis) occurred in 4 (1%) of 411<br \/>\n      patients, including Grade 2 or 3 cases in 1 (0.2%) and 2 (0.5%) patients<br \/>\n      respectively, receiving KEYTRUDA. Monitor patients for signs and<br \/>\n      symptoms of colitis. Administer corticosteroids for Grade 2 or greater<br \/>\n      colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue<br \/>\n      KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Hepatitis (including autoimmune hepatitis) occurred in 2 (0.5%) of 411<br \/>\n      patients, including a Grade 4 case in 1 (0.2%) patient, receiving<br \/>\n      KEYTRUDA. Monitor patients for changes in liver function. Administer<br \/>\n      corticosteroids for Grade 2 or greater hepatitis and, based on severity<br \/>\n      of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 2 (0.5%) of 411 patients, including a Grade 2<br \/>\n      case in 1 and a Grade 4 case in 1 (0.2% each) patient, receiving<br \/>\n      KEYTRUDA. Monitor for signs and symptoms of hypophysitis. Administer<br \/>\n      corticosteroids for Grade 2 or greater hypophysitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; withhold or discontinue for Grade 3; and permanently<br \/>\n      discontinue KEYTRUDA for Grade 4 hypophysitis.\n    <\/p>\n<p>\n      Nephritis occurred in 3 (0.7%) patients receiving KEYTRUDA, consisting<br \/>\n      of one case of Grade 2 autoimmune nephritis (0.2%) and two cases of<br \/>\n      interstitial nephritis with renal failure (0.5%), one Grade 3 and one<br \/>\n      Grade 4. Monitor patients for changes in renal function. Administer<br \/>\n      corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for<br \/>\n      Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 5 (1.2%) of 411 patients, including Grade 2<br \/>\n      or 3 cases in 2 (0.5%) and 1 (0.2%) patients respectively, receiving<br \/>\n      KEYTRUDA. Hypothyroidism occurred in 34 (8.3%) of 411 patients,<br \/>\n      including a Grade 3 case in 1 (0.2%) patient, receiving KEYTRUDA.<br \/>\n      Thyroid disorders can occur at any time during treatment. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer corticosteroids for Grade 3 or greater hyperthyroidism.<br \/>\n      Withhold KEYTRUDA for Grade 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 hyperthyroidism. Isolated hypothyroidism may be managed with<br \/>\n      replacement therapy without treatment interruption and without<br \/>\n      corticosteroids.\n    <\/p>\n<p>\n      Other clinically important immune-mediated adverse reactions can occur.<br \/>\n      The following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% of patients treated with KEYTRUDA: exfoliative<br \/>\n      dermatitis, uveitis, arthritis, myositis, pancreatitis, hemolytic<br \/>\n      anemia, partial seizures arising in a patient with inflammatory foci in<br \/>\n      brain parenchyma, adrenal insufficiency, myasthenic syndrome, optic<br \/>\n      neuritis, and rhabdomyolysis.\n    <\/p>\n<p>\n      For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement of the adverse reaction to Grade 1 or<br \/>\n      less, initiate corticosteroid taper and continue to taper over at least<br \/>\n      1 month. Restart KEYTRUDA if the adverse reaction remains at Grade 1 or<br \/>\n      less. Permanently discontinue KEYTRUDA for any severe or Grade 3<br \/>\n      immune-mediated adverse reaction that recurs and for any<br \/>\n      life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA may cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      For the treatment of advanced melanoma, KEYTRUDA was discontinued for<br \/>\n      adverse reactions in 6% of 89 patients who received the recommended dose<br \/>\n      of 2 mg\/kg and 9% of 411 patients across all doses studied. Serious<br \/>\n      adverse reactions occurred in 36% of patients receiving KEYTRUDA. The<br \/>\n      most frequent serious adverse drug reactions reported in 2% or more of<br \/>\n      patients were renal failure, dyspnea, pneumonia, and cellulitis.\n    <\/p>\n<p>\n      The most common adverse reactions (reported in \u226520% of patients) were<br \/>\n      fatigue (47%), cough (30%), nausea (30%), pruritus (30%), rash (29%),<br \/>\n      decreased appetite (26%), constipation (21%), arthralgia (20%), and<br \/>\n      diarrhea (20%).\n    <\/p>\n<p>\n      The recommended dose of KEYTRUDA is 2 mg\/kg administered as an<br \/>\n      intravenous infusion over 30 minutes every three weeks until disease<br \/>\n      progression or unacceptable toxicity. No formal pharmacokinetic drug<br \/>\n      interaction studies have been conducted with KEYTRUDA. It is not known<br \/>\n      whether KEYTRUDA is excreted in human milk. Because many drugs are<br \/>\n      excreted in human milk, instruct women to discontinue nursing during<br \/>\n      treatment with KEYTRUDA. Safety and effectiveness of KEYTRUDA have not<br \/>\n      been established in pediatric patients.\n    <\/p>\n<p>\n      <b>About Lung Cancer<\/b>\n    <\/p>\n<p>\n      Lung cancer, which forms in the tissues of the lungs, usually within<br \/>\n      cells lining the air passages, is the leading cause of cancer death<br \/>\n      worldwide. Each year, more people die of lung cancer than die of colon,<br \/>\n      breast, and prostate cancers combined. The two main types of lung cancer<br \/>\n      are non-small cell lung cancer (NSCLC) and small cell lung cancer<br \/>\n      (SCLC). NSCLC is the most common type of lung cancer, accounting for<br \/>\n      about 85 percent of all cases. The five-year relative survival rate for<br \/>\n      all advanced or metastatic (Stage IV) lung cancers combined is estimated<br \/>\n      to be four percent.\n    <\/p>\n<p>\n      <b>About PD-L1 and PD-L1 Expression<\/b>\n    <\/p>\n<p>\n      PD-L1, also called programmed death-ligand 1, is a protein expressed on<br \/>\n      many types of cells, including some cancer cells. Under normal<br \/>\n      conditions, the interaction of PD-L1 with another protein, called<br \/>\n      programmed death receptor-1 (PD-1), serves as an important immune system<br \/>\n      checkpoint, keeping the immune system in balance and preventing the body<br \/>\n      from attacking its own cells when inflammation or an infection is<br \/>\n      present. When cancerous tumors express PD-L1, however, they are able to<br \/>\n      escape detection and destruction by cytotoxic T-cells \u2013 a type of<br \/>\n      cancer-killing immune cell \u2013 allowing the tumor to survive and grow.<br \/>\n      Tumor PD-L1 expression has been observed at varying levels across many<br \/>\n      tumor types, including breast, lung and bladder cancer. High levels of<br \/>\n      PD-L1 expression, called overexpression, are under investigation for<br \/>\n      potential use as a way to help identify patients with an enhanced<br \/>\n      likelihood to respond to certain immune-based treatment approaches.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into biomedical<br \/>\n      innovations to help people with cancer worldwide. For Merck Oncology,<br \/>\n      helping people fight cancer is our passion, supporting accessibility to<br \/>\n      our cancer medicines is our commitment, and pursuing research in<br \/>\n      immuno-oncology is our focus to potentially bring new hope to people<br \/>\n      with cancer. For more information about our oncology clinical trials,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51082747&amp;newsitemid=20150419005030&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=2&amp;md5=65a8fa4bfa679e82cb676f48191c4216\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=51082747&amp;newsitemid=20150419005030&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=0c3aad49dce4482f40a7646a315f8e9a\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fmerck&amp;esheet=51082747&amp;newsitemid=20150419005030&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=4907fc032d75a4b2f008752023c1c71f\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51082747&amp;newsitemid=20150419005030&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=95c4c3ce31ddbc5a171bcb8a54a16d6b\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2Fuser%2FMerck&amp;esheet=51082747&amp;newsitemid=20150419005030&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=a9169a785ac8911c7dcb395a85ec81fd\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2014 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51082747&amp;newsitemid=20150419005030&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=795afc587d7006a8096ef0442bf63d64\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n      # # #\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51082747&amp;newsitemid=20150419005030&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=8&amp;md5=8ba8731508433185f94b72c4e8d78d9c\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><\/a><b><br \/>\n      and the Medication Guide for KEYTRUDA at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51082747&amp;newsitemid=20150419005030&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=9&amp;md5=5efd2ab9029a66f6c24b35f8e8d0233d\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><\/a><b>.<\/b>\n    <\/p>\n<p class=\"bwalignl\">\n      ____________________________\n    <\/p>\n<p>\n      <sup>1<\/sup> Original release distributed on Sunday, April 19, 2015<br \/>\n      listed ORR as 45.4 percent; Release corrected on Wednesday, May 20, 2015<br \/>\n      to reflect ORR of 45.2 percent\n    <\/p>\n<p>\n      <sup>2<\/sup> Original release distributed on Sunday, April 19, 2015<br \/>\n      listed median duration of response for the \u226550 percent PD-L1 expression<br \/>\n      sub-group as 12.4 months (2+ to 22.8+); Release corrected on Wednesday,<br \/>\n      May 20, 2015 to reflect median duration of response for the \u226550 percent<br \/>\n      PD-L1 expression sub-group as 12.5 months (2.1+ to 23.3)\n    <\/p>\n<p>\n      <sup>3<\/sup> Original release distributed on Sunday, April 19, 2015<br \/>\n      listed median duration of response for the 1-49 percent PD-L1 expression<br \/>\n      sub-group as 10.3 months (1.4+ to 10.3+); Release corrected on<br \/>\n      Wednesday, May 20, 2015 to reflect median duration of response for the<br \/>\n      1-49 percent PD-L1 expression sub-group as 7.2 months (1.4+ to 8.3+)\n    <\/p>\n<p>\n      <sup>4<\/sup> Original release distributed on Sunday, April 19, 2015<br \/>\n      listed median duration of response for the less than 1 percent PD-L1<br \/>\n      expression sub-group as not reached (0.9+ to 10.8+); Release corrected<br \/>\n      on Wednesday, May 20, 2015 to reflect median duration of response for<br \/>\n      the less than 1 percent PD-L1 expression sub-group as not reached (1.0+<br \/>\n      to 10.8+)\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150419005030r4&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Media:<br \/>Pamela Eisele, 267-305-3558<br \/>Claire Mulhearn,        908-236-1118<br \/>or<br \/>Investors:<br \/>Joseph Romanelli, 908-740-1986<br \/>Justin        Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from KEYNOTE-001, a Phase 1b study evaluating KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in na\u00efve and previously-treated patients with advanced non-small cell lung cancer (NSCLC). In an analysis of 313 patients from a validation data set for tumor PD-L1 expression, overall-response rate (ORR) was 45.2 percent 1 (95% CI, 33.5-57.3) in patients with greater than or equal to (\u2265) 50 percent of tumor cells positive for PD-L1 expression (n=73). In the other PD-L1 subgroups, ORR was 16.5 percent (95% CI, 9.9-25.1) in patients with 1-49 percent tumor cells positive (n=103) and 10.7 percent (95% CI, 2.3-28.2) in patients with less than 1 percent tumor cells positive (n=28) for PD-L1 expression. In the total study population, ORR was 19.4 percent (95% CI, 16.0-23.2) (n=495), which was consistent with data previously presented from this study. These data from KEYNOTE-001 will be<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,55,289],"class_list":["post-745221","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with KEYTRUDA\u00ae (pembrolizumab) Presented at AACR Annual Meeting and Published in the New England Journal of Medicine - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/treatment-of-advanced-non-small-cell-lung-cancer-nsclc-with-keytruda-pembrolizumab-presented-at-aacr-annual-meeting-and-published-in-the-new-england-journal-of-medicine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with KEYTRUDA\u00ae (pembrolizumab) Presented at AACR Annual Meeting and Published in the New England Journal of Medicine - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from KEYNOTE-001, a Phase 1b study evaluating KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in na\u00efve and previously-treated patients with advanced non-small cell lung cancer (NSCLC). In an analysis of 313 patients from a validation data set for tumor PD-L1 expression, overall-response rate (ORR) was 45.2 percent 1 (95% CI, 33.5-57.3) in patients with greater than or equal to (\u2265) 50 percent of tumor cells positive for PD-L1 expression (n=73). In the other PD-L1 subgroups, ORR was 16.5 percent (95% CI, 9.9-25.1) in patients with 1-49 percent tumor cells positive (n=103) and 10.7 percent (95% CI, 2.3-28.2) in patients with less than 1 percent tumor cells positive (n=28) for PD-L1 expression. In the total study population, ORR was 19.4 percent (95% CI, 16.0-23.2) (n=495), which was consistent with data previously presented from this study. These data from KEYNOTE-001 will be\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/treatment-of-advanced-non-small-cell-lung-cancer-nsclc-with-keytruda-pembrolizumab-presented-at-aacr-annual-meeting-and-published-in-the-new-england-journal-of-medicine\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/treatment-of-advanced-non-small-cell-lung-cancer-nsclc-with-keytruda-pembrolizumab-presented-at-aacr-annual-meeting-and-published-in-the-new-england-journal-of-medicine\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/treatment-of-advanced-non-small-cell-lung-cancer-nsclc-with-keytruda-pembrolizumab-presented-at-aacr-annual-meeting-and-published-in-the-new-england-journal-of-medicine\\\/\",\"name\":\"Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with KEYTRUDA\u00ae (pembrolizumab) Presented at AACR Annual Meeting and Published in the New England Journal of Medicine - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-04-19T07:30:00+00:00\",\"dateModified\":\"2025-11-07T06:25:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/treatment-of-advanced-non-small-cell-lung-cancer-nsclc-with-keytruda-pembrolizumab-presented-at-aacr-annual-meeting-and-published-in-the-new-england-journal-of-medicine\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/treatment-of-advanced-non-small-cell-lung-cancer-nsclc-with-keytruda-pembrolizumab-presented-at-aacr-annual-meeting-and-published-in-the-new-england-journal-of-medicine\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/treatment-of-advanced-non-small-cell-lung-cancer-nsclc-with-keytruda-pembrolizumab-presented-at-aacr-annual-meeting-and-published-in-the-new-england-journal-of-medicine\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with KEYTRUDA\u00ae (pembrolizumab) Presented at AACR Annual Meeting and Published in the New England Journal of Medicine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with KEYTRUDA\u00ae (pembrolizumab) Presented at AACR Annual Meeting and Published in the New England Journal of Medicine - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/treatment-of-advanced-non-small-cell-lung-cancer-nsclc-with-keytruda-pembrolizumab-presented-at-aacr-annual-meeting-and-published-in-the-new-england-journal-of-medicine\/","og_locale":"en_US","og_type":"article","og_title":"Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with KEYTRUDA\u00ae (pembrolizumab) Presented at AACR Annual Meeting and Published in the New England Journal of Medicine - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from KEYNOTE-001, a Phase 1b study evaluating KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in na\u00efve and previously-treated patients with advanced non-small cell lung cancer (NSCLC). In an analysis of 313 patients from a validation data set for tumor PD-L1 expression, overall-response rate (ORR) was 45.2 percent 1 (95% CI, 33.5-57.3) in patients with greater than or equal to (\u2265) 50 percent of tumor cells positive for PD-L1 expression (n=73). In the other PD-L1 subgroups, ORR was 16.5 percent (95% CI, 9.9-25.1) in patients with 1-49 percent tumor cells positive (n=103) and 10.7 percent (95% CI, 2.3-28.2) in patients with less than 1 percent tumor cells positive (n=28) for PD-L1 expression. In the total study population, ORR was 19.4 percent (95% CI, 16.0-23.2) (n=495), which was consistent with data previously presented from this study. These data from KEYNOTE-001 will be","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/treatment-of-advanced-non-small-cell-lung-cancer-nsclc-with-keytruda-pembrolizumab-presented-at-aacr-annual-meeting-and-published-in-the-new-england-journal-of-medicine\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:15+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/treatment-of-advanced-non-small-cell-lung-cancer-nsclc-with-keytruda-pembrolizumab-presented-at-aacr-annual-meeting-and-published-in-the-new-england-journal-of-medicine\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/treatment-of-advanced-non-small-cell-lung-cancer-nsclc-with-keytruda-pembrolizumab-presented-at-aacr-annual-meeting-and-published-in-the-new-england-journal-of-medicine\/","name":"Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with KEYTRUDA\u00ae (pembrolizumab) Presented at AACR Annual Meeting and Published in the New England Journal of Medicine - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-04-19T07:30:00+00:00","dateModified":"2025-11-07T06:25:15+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/treatment-of-advanced-non-small-cell-lung-cancer-nsclc-with-keytruda-pembrolizumab-presented-at-aacr-annual-meeting-and-published-in-the-new-england-journal-of-medicine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/treatment-of-advanced-non-small-cell-lung-cancer-nsclc-with-keytruda-pembrolizumab-presented-at-aacr-annual-meeting-and-published-in-the-new-england-journal-of-medicine\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/treatment-of-advanced-non-small-cell-lung-cancer-nsclc-with-keytruda-pembrolizumab-presented-at-aacr-annual-meeting-and-published-in-the-new-england-journal-of-medicine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with KEYTRUDA\u00ae (pembrolizumab) Presented at AACR Annual Meeting and Published in the New England Journal of Medicine"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"2c01d220-d0a9-4961-9d9d-342e52498822","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Treatment-of-Advanced-Non-Small-Cell-Lung-Cancer-NSCLC-with-KEYTRUDA-pembrolizumab-Presented-at-AACR-Annual-Meeting-and-Published-in--3QCVE.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745221","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745221\/revisions"}],"predecessor-version":[{"id":3674656,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745221\/revisions\/3674656"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745221"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745221"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}